Q1 EPS Estimate for Edwards Lifesciences Lifted by Analyst

Key Points

• Zacks Research has raised its Q1 2026 earnings per share (EPS) estimate for Edwards Lifesciences from $0.63 to $0.64, reflecting a positive outlook for the medical research company.
• The company reported Q2 2026 EPS estimates of $0.70 and full-year 2026 earnings projected at $2.74, contributing to a consensus full-year earnings forecast of $2.45 per share for 2023.
• Edwards Lifesciences has received multiple upgrades from analysts, with price targets ranging from $81.00 to $100.00, indicating strong confidence in the company's performance going forward.

Edwards Lifesciences Corporation (NYSE:EW - Free Report) - Research analysts at Zacks Research lifted their Q1 2026 earnings per share estimates for Edwards Lifesciences in a report released on Wednesday, August 13th. Zacks Research analyst Team now expects that the medical research company will post earnings of $0.64 per share for the quarter, up from their previous forecast of $0.63. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.45 per share. Zacks Research also issued estimates for Edwards Lifesciences' Q2 2026 earnings at $0.70 EPS, Q4 2026 earnings at $0.70 EPS, FY2026 earnings at $2.74 EPS, Q2 2027 earnings at $0.77 EPS and FY2027 earnings at $3.11 EPS.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the company posted $0.70 EPS. The company's revenue was up 11.9% compared to the same quarter last year.

EW has been the topic of several other reports. Royal Bank Of Canada boosted their target price on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Barclays boosted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. Wall Street Zen raised Edwards Lifesciences from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Argus raised Edwards Lifesciences to a "strong-buy" rating in a report on Thursday, July 10th. Finally, Stifel Nicolaus upped their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a report on Friday, July 25th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $85.90.

Edwards Lifesciences Price Performance

Shares of EW stock traded up $0.72 during trading hours on Friday, hitting $79.02. The company had a trading volume of 239,246 shares, compared to its average volume of 4,476,434. The firm has a market capitalization of $46.39 billion, a price-to-earnings ratio of 11.35, a PEG ratio of 3.78 and a beta of 1.08. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences has a 12 month low of $64.00 and a 12 month high of $83.00. The firm's fifty day moving average is $77.17 and its 200 day moving average is $74.46.

Insider Activity

In related news, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Daveen Chopra sold 1,500 shares of the firm's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total transaction of $112,620.00. Following the completion of the sale, the vice president owned 33,496 shares of the company's stock, valued at $2,514,879.68. This trade represents a 4.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,084 shares of company stock valued at $2,010,382. Company insiders own 1.29% of the company's stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $266,000. Bank Pictet & Cie Europe AG increased its holdings in shares of Edwards Lifesciences by 16.7% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company's stock worth $757,000 after purchasing an additional 1,463 shares during the period. Townsquare Capital LLC increased its holdings in shares of Edwards Lifesciences by 24.8% during the fourth quarter. Townsquare Capital LLC now owns 6,501 shares of the medical research company's stock worth $481,000 after purchasing an additional 1,293 shares during the period. CreativeOne Wealth LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $201,000. Finally, United Capital Financial Advisors LLC increased its holdings in shares of Edwards Lifesciences by 64.8% during the fourth quarter. United Capital Financial Advisors LLC now owns 24,859 shares of the medical research company's stock worth $1,840,000 after purchasing an additional 9,779 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.